AC Immune initiated with a Buy at BTIG

BTIG analyst Thomas Shrader initiated coverage of AC Immune with a Buy rating and $8 price target. AC Immune is a clinical-stage biotechnology company with a broad pipeline of agents to both detect and clear the toxic proteins that drive neurodegenerative disease, the analyst tells investors in a research note. The firm says the lead program is an anti-alpha beta vaccine that targets species with a precision-engineered focus on toxic oligomers.